Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Deramo

Plastic Surgery Provo, UT Medical Doctor

NPI 1346545837 CMS profile 1382273

3550 N University Ave Ste 250, Provo, UT 84604

Open in the dashboard

General payments

$182,944

413 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Deramo of Provo, UT is reported in the CMS Open Payments database as having received $182,944 across 413 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $91,503 131
2024 General $70,630 146
2023 General $13,335 44
2022 General $2,056 37
2021 General $3,646 35
2020 General $1,375 16
2019 General $397 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Deramo
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Paul Deramo were reported at $91,503. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Paul Deramo Plastic Surgery median Middle half National median
2019 $397 $371 $122–$1,483 $163
2020 $1,375 $158 $52–$438 $114
2021 $3,646 $249 $87–$752 $132
2022 $2,056 $274 $102–$793 $149
2023 $13,335 $299 $113–$891 $160
2024 $70,630 $361 $124–$1,062 $164
2025 $91,503 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Integra LifeSciences Corporation $159,586 199 payments
  2. Medical Device Business Services, Inc. $6,793 26 payments
  3. Allergan Inc. $4,692 48 payments
  4. AbbVie, Inc. $3,765 45 payments
  5. AxoGen $3,182 17 payments
  6. RTI Surgical, Inc $1,200 1 payment
  7. Ethicon US, LLC $1,187 25 payments
  8. Checkpoint Surgical, Inc $404 3 payments
  9. Aroa Biosurgery Incorporated $315 6 payments
  10. Davol Inc. $251 9 payments
  11. Other $1,570 34 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $110,073 36 payments
  2. Travel and Lodging $53,425 94 payments
  3. Food and Beverage $16,943 279 payments
  4. Long term medical supply or device loan $1,303 3 payments
  5. Honoraria $1,200 1 payment
Products named General payments · program years 2019–2025
  1. Integra Recon-Skin And Wound $151,919 177 payments
  2. Integra Recon-Skin And Wound $151,909 176 payments
  3. INTEGRA DERMAL REGENERATION TEMPLATE $12,078 107 payments
  4. Integra Recon-Skin And Wound $12,062 106 payments
  5. PRIMATRIX $11,920 102 payments
  6. VISTASEAL $6,724 37 payments
  7. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastic Surgery $5,428 43 payments
  8. GENTRIX $4,684 18 payments
  9. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $2,643 15 payments
  10. NATRELLE SALINE-FILLED BREAST IMPLANTS Plastics $2,428 23 payments
  11. Other $24,982 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

269

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$2,059

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

27.5%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Cephalexin Generic 55 $638
Ondansetron Odt Ondansetron Brand 42 $385
Oxycodone Hcl Generic 44 $266
Methocarbamol Generic 34 $223
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 14 $202
Celecoxib Generic 24 $128
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 18 $113
Gabapentin Generic 38 $103

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$42,340

Medicare's payments for the services billed

Medicare patients

42

Average age 70

Services billed

142

25 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 69%
Diabetes 55%
Depression 40%
Chronic kidney disease 38%
Cancer 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

413 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record